培美曲塞联合顺铂治疗晚期尿路上皮癌的疗效与安全性研究  

The Efficacy and Safety of Pemetrexed plus Cisplatin on Patients with Advanced Urothelial Carcinoma

作　　者：楚晨龙[1] 周文龙[2] 赵晨晖[1] 黄滔[1] 张志伟[1] 王名伟[1] 杨安卿[1] 马斌斌[1] 忻志祥[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院卢湾分院泌尿外科,上海200020 [2]上海交通大学医学院附属瑞金医院泌尿外科,上海200025

出　　处：《现代生物医学进展》2016年第15期2864-2867,共4页Progress in Modern Biomedicine

基　　金：上海市黄浦区卫生系统重点学科建设项目(PWZXK2011-18)

摘　　要：目的:评估培美曲塞联合顺铂治疗晚期尿路上皮癌的有效性和安全性。方法:纳入在我院泌尿科治疗的65例晚期上皮癌患者。每隔3周为患者注射培美曲塞500 mg·m-2,顺铂70 mg·m-2。试验主要终点为客观缓解率(ORR),次要终点为无疾病进展期(PFS)、总生存期(OS)和毒性。采用Kaplan-Meier法计算生存率。结果:患者客观响应率为65.4%(95%CI:50.3%-78.1%),42例患者有部分缓解,11例患者疾病稳定。PFS和OS分别为7.1(95%CI:6.3-8.7)个月与15.5个月(95%CI:11.5-19.5)个月。29.2%的患者出现3级或4级嗜中性白血球减少症,无发热性中性粒细胞减少情况出现。结论:培美曲塞联合顺铂用于晚期尿路上皮癌一线治疗十分有效,且耐受性良好。Objective： To evaluate the efficacy and safety of patients with advanced urothelial carcinoma treated by pemetrexed plus cisplatin. Methods： A total of 65 patients with advanced epithelial cancer in our hospital were included. The patients were injected with 500 mg·m-2pemetrexed and 70 mg·m-2cisplatin at every fouth week. The primary endpoint for the trial objective was response rate（ORR）. The secondary endpoint were progression-free（PFS）, overall survival（OS） and toxicity. Survival rate was calculated using the Kaplan-Meier method. Results： The objective response rate of patients was 65.4%（95% CI： 50.3%-78.1%）. Fourty-two patients had partial remission, and 11 patients had disease stable. The PFS and OS were respectively 7.1 months（95% CI： 6.3-8.7） and 15.5 months（95% CI： 11.5-19.5）. There were 29.2% of patients with grade 3 or 4 neutropenia disease, and no febrile neutropenia situation appeared.Conclusion： Pemetrexed in combination with cisplatin is very effective and well tolerated in the first-line treatment of advanced urothelial cancer.

关 键 词：尿路上皮癌 培美曲塞 疗效 

分 类 号：R737[医药卫生—肿瘤]